A. Hsu

A phase I/II trial of sorafenib (S) with bevacizumab (B) in metastatic renal cell cancer (mRCC) patients (Pts).

K. Flaherty, M. Atkins, J. Sosman, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postchemotherapy MRI Overestimates Residual Disease Compared with Histopathology in Responders to Neoadjuvant Therapy for Locally Advanced Breast Cancer

L. Horvath, G. Chung, B. Haffty, 2006, Cancer journal.

Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.

A. Hsu, L. Malizzia, 2008, Clinical journal of oncology nursing.

Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC)

Mace L. Rothenberg, Michael B. Atkins, Jeffrey A. Sosman, 2008 .

Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN)

A. Berkenblit, A. Strahs, P. Ruff, 2007 .

Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer

M. Reiss, D. Zelterman, G. Chung, 2005, Oncology.

Final results of a phase I trial of sorafenib and bevacizumab in patients with metastatic renal cell cancer (mRCC).

K. Flaherty, M. Atkins, J. Sosman, 2007 .

Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.

A. Hsu, L. Malizzia, 2008, Clinical journal of oncology nursing.